Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs) and utilize them to evade immune surveillance and mediate metastasis. tBregs directly inhibit CD4+ and CD8+ T cell activity in a cell contact-dependent manner, induce FoxP3+ T cell activity, and promote Treg-dependent metastasis. The National Institute on Aging's Immunotherapeutics Unit, is seeking parties interested in licensing or co-development of regulatory B cells to control autoimmune diseases and strategies that inactivate tBregs to control cancer immune escape.
Researchers at the National Institute on Aging (NIA) have developed a novel strategy for rendering weakly or non-immunogenic, shared (between self and tumor) antigens immunogenic, or able to produce an immune response. Further, they have created therapeutic polypeptides comprising tumor-associated embryonic antigens and chemoattractant ligands. Cancers targeted by these developments include breast, renal, lung, ovarian, and hematological cancers.
Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation. The NIA seeks licensing or co-development partners to commercialize this technology.
Researchers at the National Institute on Aging working on cancer immunotherapy and detection report the use of SPANX-B polypeptides in the treatment and identification of cancer. Specific human malignancies targeted for the treatments disclosed include melanoma and lung, colon, renal, ovarian and breast carcinomas. The NIA seeks parties interested in licensing or collaborative research to further develop, evaluate, or commercialize SPANX-B polypeptides in the treatment and identification of cancer.